Cytori Therapeutics Inc (CYTX) now the company's industry has 12.57 P/E and the sector P/E is 16.5. Its opening price on the last trading day was $0.54.
05/12/2015 - Ascendiant Capital Markets began new coverage on Cytori Therapeutics Inc giving the company a "buy" rating. Days to cover decreased 0.0 to 4.0 and the short interest percentage is 0.06% as of September 15. The analysts estimated mean EPS at -0.15 while the high and low EPS estimate stand at -0.14 and -0.17 respectively. Stock's distance from 52 week High is -73.7% and the distance from 52 week Low is 97.92%. Volume was down 95.28% under the stocks average daily volume.
Below is a list of Cytori Therapeutics Inc (NASDAQ:CYTX) latest ratings and price target changes. The quarterly performance for the stock is -51.36%, while the half-yearly performance is -68.61%.
The ratios of the return on assets (ROA) and the return on owner's equity (ROE) are the most used profitability ratios in the analysis while ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business. For the most recent quarter, quick ratio was 0.6, current ratio was 0.9, LT Debt/Equity ratio was 1.27 and Total Debt/Equity ratio stands at 2.18, while Payout ratio is 0.
Media stories about Cytori Therapeutics (NASDAQ:CYTX) have been trending somewhat positive on Monday, Alpha One Sentiment reports. The 50 day moving average moved up $0.17 and the 200 day average went down $-0.26 or -31.8685%. The company's 50-day moving average is $1.04 and its 200-day moving average is $1.47.
The company's diluted EPS for trailing twelve months was -1.03.
As of the latest earnings report the EPS was $-1.00 and is estimated to be $-0.60 for the current year with 34,716,000 shares now outstanding. Analysts expect next quarter's EPS to be $-0.10 and the next full year EPS is anticipated to be $-0.43. During the same quarter in the prior year, the company posted ($0.03) earnings per share.
Annual EPS growth Past 5 years is 32.5 percent.
5 year sales growth rate is an important factor for valuation analysis, the industry's and the sector's growth for next 5 years ticked at -3.17 and -7.83 respectively.
The company P/E (price to earnings) ratio is 0 and Forward P/E ratio is 0. The company maintains price to book ratio of 0.96.
Cytori Therapeutics (NASDAQ:CYTX) remained flat at $1.03 during midday trading on Monday. The value of the investment in CYTX increased from $2,000 to $10,000 a change of 400.0% for the reporting period. Last quarter, the company saw 969,000 in total revenues. Finally, Zacks Investment Research downgraded Cytori Therapeutics from a "hold" rating to a "sell" rating in a report on Monday, February 20th.
According to InspireMD, Inc.'s Insider ownership is at 0.70%.